Mode
Text Size
Log in / Sign up
N/A N=60 Randomized Treatment

Cognitive Reappraisal Training for Borderline Personality

Borderline Personality Disorder

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Change in PINES Network Activity — 0.15; 0.14; 0.12; 012 BOLD Signal

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cognitive Reappraisal by Distancing (Behavioral); Control Downregulate Condition (Behavioral)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Icahn School of Medicine at Mount Sinai
Primary completion
Jun 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in PINES Network Activity
0.15; 0.14; 0.12; 012
PRIMARY
Change in Zanarini Rating Scale for Borderline Personality (ZAN-BPD)
15.22; 12.86; 10; 9.38
SECONDARY
Change in ZAN-BPD Sector Scores
5.33; 5; 4; 2.71; 1.89; 2.57
SECONDARY
Change in Affective Lability Scale Total (ALS)
95; 104; 82.91; 93.27; 74.3; 85.8
SECONDARY
Change in Perceived Stress Scale (PSS)
2.28; 2.36; 2.19; 2.17; 2.22; 2.28
SECONDARY
Change in Difficulty in Emotion Regulation Scale Scores (DERS)
119.15; 126.58; 109.09; 117.99; 110.2; 112.70
SECONDARY
Change in Beck Depression Scale Score (BDI)
24.62; 20.08; 22.09; 15.36; 22.3; 16.3
SECONDARY
Change in State-Trait Anxiety Scale Score (STAXI)
84.54; 90.5; 86.91; 87.36; 90.9; 91.5

Summary

Previous work by the study group convinced the study team to pursue development of focused cognitive reappraisal training as a novel approach to treatment of BPD, either as stand-alone treatment or in concert with evidence-based treatments of BPD. The present proposal aims to refine and test a proposed clinical intervention for BPD patients, training in reappraisal-by-distancing, in terms of its ability to influence hypothesized neural and behavioral targets and, once that is established, to demonstrate its ability improve clinically relevant outcome measures.

Eligibility Criteria

Inclusion Criteria

  • Medically healthy men and women with Borderline Personality Disorder who are mentally competent and give informed voluntary written consent.
  • Subjects who are being treated with psychotherapy or psychopharmacotherapy will be included so long as there has been no change in that treatment over the preceding 2 months.

Exclusion Criteria

  • Age > 55
  • Criteria for Schizotypal Personality Disorder or Avoidant Personality Disorder. SPD is excluded to avoid possible confound from the restricted affect that characterizes SPD and co-morbid AvPD subjects will be excluded because the researchers have shown that their patterns of neural activity in emotion processing are distinct from BPD subjects.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04967222). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search